Successful translation of potential cancer chemotherapeutic drugs to the clinic depends on sufficient predictability of response in the human system through in vitro simulations. High expenditure and longer duration in preclinical and clinical research urge the enhancement of effective in vitro drug screening. 3D models emulate cell morphology, cell–cell and cell–matrix interactions and are physiologically more relevant for predicting drug responses for complex heterogenic cancers, widely replacing conventional cultures. Bioprinting and microfluidic technology facilitate tissue mimetic model construction and multifaceted simulation of physiology, respectively, promising more-appropriate predictability of drug interactions. Precisely, organotypic tissue constructs assembled using cell-laden matrices or organ-on-a-chip serve as realistic tissue models. This review projects the progress toward biomimetic tissue model development, highlighting the emergence of bioprinting and microfluidic technology in in vitro cancer drug screening and pertaining challenges.

将潜在的癌症化疗药物成功转化为临床取决于通过体外模拟对人体系统反应的充分可预测性。临床前和临床研究的高支出和更长的持续时间敦促提高体外有效药物筛选。3D 模型模拟细胞形态、细胞 - 细胞和细胞 - 基质相互作用，并且在生理上更适合预测复杂异源癌症的药物反应，广泛取代传统培养。生物打印和微流体技术分别促进了组织模拟模型的构建和生理学的多方面模拟，有望更恰当地预测药物相互作用。准确地说，使用载有细胞的基质或芯片上的器官组装的器官型组织结构可用作真实的组织模型。本综述预测了仿生组织模型开发的进展，强调了生物打印和微流体技术在体外癌症药物筛选和相关挑战中的出现。